Clinical Trials Logo

Chronic Nephropathy clinical trials

View clinical trials related to Chronic Nephropathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00298129 Completed - Diabetes Mellitus Clinical Trials

Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease

Start date: February 2004
Phase: N/A
Study type: Observational

Many patients with chronic renal disease show a loss of the nocturnal decline of blood pressure (non-dipper). However, the mechanism is not yet fully understood. We evaluate 24-hour blood pressure in patients with chronic renal disease using an ambulatory blood pressure monitoring device (A & D TM2425). We also analyze the power spectrum of heart rate variability as an index of autonomic cardiovascular modulation using the same device.

NCT ID: NCT00276133 Completed - Chronic Nephropathy Clinical Trials

Effects of Atorvastatin Versus Probucol on Small Dense LDL

Start date: January 2004
Phase: Phase 4
Study type: Interventional

Small dense low-density lipoprotein (LDL) plays an important role in causing glomerular injury through conversion to an oxidatively modified form of LDL. However, few studies evaluated the effects of antilipidemic agents on the LDL particle size and renoprotective actions in hyperlipidemic patients with non-diabetic nephropathy.

NCT ID: NCT00199927 Completed - Hypertension Clinical Trials

Statins in Proteinuric Nephropathies

ESPLANADE
Start date: March 2003
Phase: Phase 3
Study type: Interventional

End stage renal disease (ESRD) is rapidly growing worldwide. Patients with ESRD have increased morbidity and mortality mostly because of a dramatic excess of cardiovascular disease. Thus, preventing or limiting the progression of chronic nephropathies, in addition to limit the incidence of ESRD, may also postpone death. Drugs that inhibit the renin angiotensin system, such as Angiotensin-Converting-Enzyme inhibitors (ACEi) and Angiotensin II receptor antagonists (ATA), are reno- and cardio-protective in the long-term. There are data that statins,in addition to limit cardiovascular events may have specific reno-protective properties. Thus we designed a study aimed to evaluate whether statins associated to ACEi and ATA may have an additional reno-protective effect. ESPLANADE is a multicenter, prospective, randomized, parallel group study in which, after 2 months treatment with ACEi and ATA, two groups of 90 patients, with or without type 2 diabetes, are randomized to 6 months Fluvastatin (40 or 80 mg/day) treatment YES or NO.Twenty Italian Nephrology Units are involved in the trial. The study is fully coordinated by the Clinical Research Center for Rare Disease Aldo e Cele Daccò, Villa Camozzi, Ranica.